Bispecific Antibodies in the Treatment of Multiple Myeloma

Xiang Zhou; Xianghui Xiao; Klaus Martin Kortuem; Hermann Einsele

doi:10.1016/j.hoc.2023.12.003

Bispecific Antibodies in the Treatment of Multiple Myeloma

Hematol Oncol Clin North Am. 2024 Apr;38(2):361-381. doi: 10.1016/j.hoc.2023.12.003. Epub 2024 Jan 9.

Authors

Xiang Zhou¹, Xianghui Xiao¹, Klaus Martin Kortuem¹, Hermann Einsele²

Affiliations

¹ Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
² Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany. Electronic address: Einsele_H@ukw.de.

PMID: 38199897
DOI: 10.1016/j.hoc.2023.12.003

Abstract

The treatment of multiple myeloma (MM) is evolving rapidly. In recent years, T-cell-based novel immunotherapies emerged as new treatment strategies for patients with relapsed/refractory MM, including highly effective new options like chimeric antigen receptor (CAR)-modified T cells and bispecific antibodies (bsAbs). Currently, B-cell maturation antigen is the most commonly used target antigen for CAR T-cell and bsAb therapies in MM. Results from different clinical trials have demonstrated promising efficacy and acceptable safety profile of bsAb in RRMM.

Keywords: CAR T cell; Immunotherapy bispecific antibody; Multiple myeloma.

Publication types

Review

MeSH terms

Antibodies, Bispecific* / therapeutic use
Humans
Immunotherapy
Immunotherapy, Adoptive / adverse effects
Multiple Myeloma* / therapy

Substances

Antibodies, Bispecific